Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06400303
PHASE1/PHASE2

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Sponsor: Kyverna Therapeutics

View on ClinicalTrials.gov

Summary

A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Systemic Sclerosis

Official title: KYSA-5: A Phase 1/2, Open-Label, Multicentre Study of KYV 101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

3

Start Date

2024-08-06

Completion Date

2027-03

Last Updated

2025-10-08

Healthy Volunteers

No

Interventions

BIOLOGICAL

KYV-101

Anti-CD19 CAR-T cell therapy

DRUG

Standard lymphodepletion regimen

Standard lymphodepletion regimen

Locations (2)

Stanford University Medical Center

Palo Alto, California, United States

Northwell Health

Great Neck, New York, United States